Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A